This is the authors' abstract. We don't add key points for this paper.
// Brian H. Kushner 1 , Michael P. LaQuaglia 1 , Shakeel Modak 1 , Suzanne L. Wolden 2 , Ellen M. Basu 1 , Stephen S. Roberts 1 , Kim Kramer 1 , Karima Yataghene 1 , Irene Y. Cheung 1 and Nai-Kong V. Cheung 1 1 Department of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA 2 Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA Correspondence to: Brian H. Kushner, email: kushnerb@mskcc.org Keywords: neuroblastoma; anti-G D2 antibody; autologous transplantation; cytokine; MYCN amplification Received: May 07, 2017 Accepted: August 07, 2017 Published: August 24, 2017 ABSTRACT High-risk neuroblastoma (HR-NB) includes MYCN -amplified stage 2/3, but reports covering anti-G D2 immunotherapy, which recently became standard for HR-NB, do not provide details on this subset. We now report on all 20 MYCN -amplified stage 2/3 patients who received induction chemotherapy at our center during the era of consolidation with anti-G D2 antibody 3F8/ granulocyte-macrophage colony-stimulating factor (GM-CSF) (2000-2015). Early in this period, consolidation included autologous stem-cell transplantation (ASCT). Event-free survival (EFS) and overall survival (OS) were estimated using Kaplan-Meier analyses. With induction, 19/20 (95%) patients achieved complete/very good partial remission (CR/VGPR) but one had progressive disease with early death. One responder did not receive consolidation and died of relapse. Five-year post-diagnosis EFS/OS rates for all 20 patients were 72%/84%. The 18 CR/VGPR patients who received consolidation had EFS/OS 81%/94% at five years from starting 3F8/GM-CSF: 4/4 ASCT patients remained relapse-free, while 11/14 non-ASCT patients remained relapse-free and two of the three relapsed patients achieved 2 nd CR (consolidated by retreatment with 3F8/GM-CSF) and remained in 2 nd CR at 36+ and 95+ months post-relapse. The 14 non-ASCT patients had EFS/OS 73.5%/93% at five years from starting 3F8/GM-CSF. This subset appears to have a good prognosis with contemporary multi-modality therapy, possibly even without ASCT.
Answers are grounded in this paper and cite their sources.
No takes yet. Share an insight, caveat, or question.
Kushner et al. (2017) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: